13815-16-2 Usage
Uses
Used in Cancer Treatment:
Triaminomonochloro platinum (II) chloride is used as a chemotherapy agent for its potential antineoplastic activity. It is particularly effective in treating cancer due to its inhibitory effect on DNA synthesis, which arises from platinum binding and causing DNA cross-linking. This process inhibits DNA repair and synthesis, leading to cell-cycle arrest and apoptosis, or programmed cell death. Triaminomonochloro platinum (II) chloride's relatively low toxicity to normal cells makes it a significant candidate for chemotherapy.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Triaminomonochloro platinum (II) chloride is used as a potential drug candidate for cancer treatment. Its mechanism of action involves inhibiting DNA synthesis through platinum binding and causing DNA cross-linking, which disrupts DNA repair and synthesis. This leads to cell-cycle arrest and apoptosis, making it a promising option for developing new cancer therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 13815-16-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,8,1 and 5 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 13815-16:
(7*1)+(6*3)+(5*8)+(4*1)+(3*5)+(2*1)+(1*6)=92
92 % 10 = 2
So 13815-16-2 is a valid CAS Registry Number.
13815-16-2Relevant academic research and scientific papers
Glennon, Carmel S.,Hand, Timothy D.,Sykes, A. Geoffrey
, p. 19 - 23 (1980)
The kinetics of 2:1 V(2+) and (2+) reductions of six Pt(IV) complexes: trans-(2+), trans-(2+), (3+), (3+), mer-(3+), and (2-) have been studied.Reactions involve one-equivalent changes, Pt(IV) -> Pt(III) -> Pt(II) where the first step is rate determining and Pt(III) is a transient intermediate.A linear correlation of second-order rate constants (15 deg C) kV and kRu, logkV=0.89logkRu - 1.68, is obtained at l=0.10M (LiClO4), consistent with outer-sphere reactions, and non-utilization (by V(2+)) of inner-sphere pathways involving Cl(1-) and Br(1-) br idges.The occurrence of outer-sphere reactions appears to preclude two equivalent changes.Rate constants for the V(2+) reductions of trans-(2+) > (3+) differ by a factor of 60, whereas those for corresponding (2+) reductions, which involve two-equivalent changes, have previously been shown to differ by a factor 1E4.Activation parameters have been determined for five of the V(2+) reductions.Those for the reduction of trans-(2+) and trans-(2+) differ significantly indicating an influence of the methyl groups.
